Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix for Prevention of Incident Dementia in Adults Aged 76+ in Finland
2025-524598-17-00Phase 4Authorised
- Sponsor
- GSK
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in Dementia, Alzheimer's disease (AD) and herpes zoster (HZ) comparing Shingrix arm with Placebo arm (2 arms). Primary endpoint: Incident diagnosis of dementia post-first dose. Planned start Mar 2026; status: authorised.
02
Drugs
Zoster vaccine recombinant
03
Conditions
DementiaAlzheimer's disease (AD)herpes zoster (HZ)
Beyond the preview
Go deeper on 2025-524598-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524598-17-00.